Dyne Therapeutics, Inc. (Nasdaq:DYN) stock fell 23% after the company announced an updated plan for obtaining U.S. Accelerated Approval for DYNE-101 in myotonic dystrophy type 1 (DM1) following a Type C meeting with the FDA.
June 17, 2025 - 14:25
By Pharos Investment Advisors Comments are Off
Dyne Therapeutics, Inc. (Nasdaq:DYN) stock fell 23% after the company announced an updated plan for obtaining U.S. Accelerated Approval for DYNE-101 in myotonic dystrophy type 1 (DM1) following a Type C meeting with the FDA.
Regulated by Hellenic Capital Market Commission
with Registration Number 5/700/10.12.2014

Copyright 2023©. All Rights Reserved